Mologen AG (ISIN DE 0006237200) has signed an agreement for use of its cell-based gene therapy with NMC Group, the leading healthcare and pharmaceutical company in the Middle East. NMC will treat tumor patients in all their hospitals in the United Arab Emirates with Mologen’s cell-based gene therapy. The cell-based therapeutics will be supplied by Mologen. The agreement marks the first success for Mologen’s recent strategic refocus in marketing of its cell-based gene therapy in the Middle East.
